{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:35:41Z","timestamp":1707525341617},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,26]]},"DOI":"10.7759\/cureus.46032","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T01:42:17Z","timestamp":1695778937000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review
"],"prefix":"10.7759","author":[{"given":"Md Fahad","family":"Hossain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Kharel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahfuza","family":"Akter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibek","family":"Parajuli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indresh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitesh","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Nurul","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert A","year":"2009","unstructured":"Engert A, Diehl V, Franklin J, et al.. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009, 27:4548-54. 10.1200\/JCO.2008.19.8820","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani S","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A, et al.. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011, 365:203-12. 10.1056\/NEJMoa1100340","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma","volume":"366","author":"Meyer RM","year":"2012","unstructured":"Meyer RM, Gospodarowicz MK, Connors JM, et al.. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012, 366:399-408. 10.1056\/NEJMoa1111961","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers JM","year":"2014","unstructured":"Raemaekers JM, Andr\u00e9 MP, Federico M, et al.. Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2014, 32:1188-94. 10.1200\/JCO.2013.51.9298","journal-title":"J Clin Oncol"},{"key":"ref5","unstructured":"FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma. (2020). Accessed. August 15, 2023: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-extends-approval-pembrolizumab-classical-hodgkin-l...."},{"key":"ref6","article-title":"Pembrolizumab","author":"Flynn JP","year":"2023","unstructured":"Flynn JP, Gerriets V. Pembrolizumab. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847184.45889.7a","article-title":"P1079: comparison of novel salvage regimens and traditional salvage chemotherapy in relapsed and refractory classic hodgkin lymphoma","volume":"6","author":"Ermann D","year":"2022","unstructured":"Ermann D, Vardell V, Zacholski E, et al.. P1079: comparison of novel salvage regimens and traditional salvage chemotherapy in relapsed and refractory classic hodgkin lymphoma. Hemasphere. 2022, 6:969-70. 10.1097\/01.HS9.0000847184.45889.7a","journal-title":"Hemasphere"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE- 204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla J","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A, et al.. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE- 204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021, 22:512-22. 10.1016\/S1470-2045(21)00005-X","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004970","article-title":"Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical Hodgkin lymphoma","volume":"6","author":"Zinzani PL","year":"2022","unstructured":"Zinzani PL, Ramchandren R, Santoro A, et al.. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed\/refractory classical Hodgkin lymphoma. Blood Adv. 2022, 6:590-9. 10.1182\/bloodadvances.2021004970","journal-title":"Blood Adv"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase ii study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen R","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, et al.. Phase ii study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017, 35:2125-32. 10.1200\/JCO.2016.72.1316","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen R","year":"2019","unstructured":"Chen R, Zinzani PL, Lee HJ, et al.. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019, 134:1144-53. 10.1182\/blood.2019000324","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand P","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V, et al.. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016, 34:3733-9. 10.1200\/JCO.2016.67.3467","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001367","article-title":"KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"4","author":"Armand P","year":"2020","unstructured":"Armand P, Kuruvilla J, Michot JM, et al.. KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020, 4:2617-22. 10.1182\/bloodadvances.2019001367","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand P","year":"2019","unstructured":"Armand P, Chen YB, Redd RA, et al.. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019, 134:22-9. 10.1182\/blood.2019000215","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3164_431","article-title":"Phase 2 KEYNOTE-B68 study: pembrolizumab every 6 weeks in relapsed\/refractory (R\/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL)","volume":"41","author":"McDonald A","year":"2023","unstructured":"McDonald A, Verburgh E, Gotti M, et al.. Phase 2 KEYNOTE-B68 study: pembrolizumab every 6 weeks in relapsed\/refractory (R\/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL). Hematol Oncol. 2023, 41:575-77.","journal-title":"Hematol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with Anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang PF","year":"2017","unstructured":"Wang PF, Chen Y, Song SY, et al.. Immune-related adverse events associated with Anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017, 8:730. 10.3389\/fphar.2017.00730","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1229","article-title":"Prioritization and sequential exclusion of articles in systematic reviews","volume":"18","author":"Saif-Ur-Rahman KM","year":"2022","unstructured":"Saif-Ur-Rahman KM, Hasan M, Hossain S, Anwar I, Hirakawa Y, Yatsuya H. Prioritization and sequential exclusion of articles in systematic reviews. Campbell Syst Rev. 2022, 18:e1229. 10.1002\/cl2.1229","journal-title":"Campbell Syst Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-89. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag S","year":"2018","unstructured":"Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018, 68:116-32. 10.3322\/caac.21438","journal-title":"CA Cancer J Clin"},{"key":"ref24","unstructured":"Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors . (2021). Accessed. August 15, 2023: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2021\/immune-checkpoint-inhibitors-melanoma-long-term-side-eff...."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1830056","article-title":"Pembrolizumab for the treatment of Hodgkin Lymphoma","volume":"20","author":"Al Hadidi SA","year":"2020","unstructured":"Al Hadidi SA, Lee HJ. Pembrolizumab for the treatment of Hodgkin Lymphoma. Expert Opin Biol Ther. 2020, 20:1275-82. 10.1080\/14712598.2020.1830056","journal-title":"Expert Opin Biol Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2061947","article-title":"An evaluation of pembrolizumab for classical Hodgkin lymphoma","volume":"15","author":"Manji F","year":"2022","unstructured":"Manji F, Laister RC, Kuruvilla J. An evaluation of pembrolizumab for classical Hodgkin lymphoma. Expert Rev Hematol. 2022, 15:285-93. 10.1080\/17474086.2022.2061947","journal-title":"Expert Rev Hematol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.02.009","article-title":"Pembrolizumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after autologous transplant and in transplant-na\u00efve patients","volume":"22","author":"Halahleh K","year":"2022","unstructured":"Halahleh K, Al Sawajneh S, Saleh Y, et al.. Pembrolizumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after autologous transplant and in transplant-na\u00efve patients. Clin Lymphoma Myeloma Leuk. 2022, 22:589-95. 10.1016\/j.clml.2022.02.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12770","article-title":"Pembrolizumab in classical Hodgkin's lymphoma","volume":"97","author":"Maly J","year":"2016","unstructured":"Maly J, Alinari L. Pembrolizumab in classical Hodgkin's lymphoma. Eur J Haematol. 2016, 97:219-27. 10.1111\/ejh.12770","journal-title":"Eur J Haematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.10.010","article-title":"Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with or without pembrolizumab maintenance therapy in patients with lymphoma","volume":"28","author":"Merryman RW","year":"2022","unstructured":"Merryman RW, Redd R, Jeter E, et al.. Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with or without pembrolizumab maintenance therapy in patients with lymphoma. Transplant Cell Ther. 2022, 28:32.e1-e10. 10.1016\/j.jtct.2021.10.010","journal-title":"Transplant Cell Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/189442-effectiveness-and-safety-of-pembrolizumab-in-recurrent-and-relapsed-classic-hodgkin-lymphoma-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:27Z","timestamp":1707509247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/189442-effectiveness-and-safety-of-pembrolizumab-in-recurrent-and-relapsed-classic-hodgkin-lymphoma-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.46032","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,26]]}}}